Primary Bone Lymphomas: Retrospective Analysis Of 42 Consecutive Cases

Telma Murias dos Santos, Juan Pablo Zumárraga, Fábio Mazetti Reaes, Carlos Henrique Maçaneiro Junior, André Mathias Baptista, Olavo Pires de Camargo

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

6 Citas (Scopus)


Objective: It is difficult to define parameters for management and factors associated with primary bone lymphoma (PBL). This article presents the experience in a single institution with 42 patients with PBL over a 16-year period (2000-2016). Methods: Fifty-five patients were retrospectively evaluated, and forty-two were included (76.3%). Results: Median age at diagnosis was 51.5 years, and median follow-up was 102.7 months. One patient had HIV. Pain in the affected site was the most prevalent symptom. The average time between symptom onset and diagnosis was 5.4 months. The vertebrae were most affected (n=16, 33.3%). According to the International Prognostic Index Score (IPI), 64.3% of the patients were classified as having low-grade lymphoma and 25.7% as low-intermediate. The most common histology was diffuse large B cell lymphoma (DLBCL) (85.7%). Immunophenotyping was CD20 positive in 93.5% of patients, and 11 patients had pathological fracture. All patients received chemotherapy and 30% of the regimens included rituximab. Thirty-eight percent of patients received radiation therapy. Overall survival was 50%, and survival median time was 80 months. Age and chemotherapy regimen influenced patient survival. Younger patients and patients who received RCHOP had better prognoses. Conclusions: The choice of chemotherapy regimen associated with age influenced survival for patients with PBL.

Idioma originalInglés
Páginas (desde-hasta)103-107
Número de páginas5
PublicaciónActa Ortopedica Brasileira
EstadoPublicada - 1 mar. 2018
Publicado de forma externa


Profundice en los temas de investigación de 'Primary Bone Lymphomas: Retrospective Analysis Of 42 Consecutive Cases'. En conjunto forman una huella única.

Citar esto